REGITINE
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Jan 1952
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
REGITINE is an injectable small-molecule drug approved in 1952 by Novartis. The specific indication and mechanism of action are not publicly disclosed in this profile. As a legacy product approaching loss of exclusivity, it likely addresses a niche therapeutic need with established clinical utility.
LOE Approaching
With LOE approaching and zero linked job openings, this product faces declining commercial relevance and likely reduced team staffing.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on REGITINE offers limited career growth potential given zero current job openings and approaching LOE. This is a maintenance role best suited for professionals managing product transitions or generic conversions rather than launching or expanding a franchise.
Brand Manager (defensive)Field Sales (generic transition support)
Worked on REGITINE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.